- Home
- DMLP vs IMNM Comparison
DMLP vs IMNM Comparison
Compare DMLP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- IMNM
- Stock Information
- Founded
- DMLP 2003
- IMNM 2006
- Country
- DMLP United States
- IMNM United States
- Employees
- DMLP N/A
- IMNM N/A
- Industry
- DMLP Oil & Gas Production
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- DMLP Energy
- IMNM Health Care
- Exchange
- DMLP Nasdaq
- IMNM Nasdaq
- Market Cap
- DMLP 1.2B
- IMNM 987.1M
- IPO Year
- DMLP N/A
- IMNM 2020
- Fundamental
- Price
- DMLP $25.44
- IMNM $13.83
- Analyst Decision
- DMLP
- IMNM Strong Buy
- Analyst Count
- DMLP 0
- IMNM 9
- Target Price
- DMLP N/A
- IMNM $24.89
- AVG Volume (30 Days)
- DMLP 83.4K
- IMNM 2.0M
- Earning Date
- DMLP 10-30-2025
- IMNM 11-12-2025
- Dividend Yield
- DMLP 12.64%
- IMNM N/A
- EPS Growth
- DMLP N/A
- IMNM N/A
- EPS
- DMLP 1.71
- IMNM N/A
- Revenue
- DMLP $161,859,000.00
- IMNM $12,589,000.00
- Revenue This Year
- DMLP N/A
- IMNM N/A
- Revenue Next Year
- DMLP N/A
- IMNM $154.70
- P/E Ratio
- DMLP $14.98
- IMNM N/A
- Revenue Growth
- DMLP 4.04
- IMNM 16.74
- 52 Week Low
- DMLP $24.01
- IMNM $5.15
- 52 Week High
- DMLP $34.88
- IMNM $15.13
- Technical
- Relative Strength Index (RSI)
- DMLP 48.57
- IMNM 67.38
- Support Level
- DMLP $25.18
- IMNM $11.25
- Resistance Level
- DMLP $25.71
- IMNM $12.00
- Average True Range (ATR)
- DMLP 0.42
- IMNM 1.01
- MACD
- DMLP -0.00
- IMNM 0.40
- Stochastic Oscillator
- DMLP 32.20
- IMNM 87.06
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.